Treatment of recurrent Clostridium difficile diarrhea

Gastroenterology and Hepatology

Volumn 2, Issue 3, 2006, Pages 203-208

  Huebner, Elizabeth S ^a   Surawicz, Christina M ^b,c,d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Department of Medicine ^*  (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Faculty Development   (United States)

Author keywords

Lactobacillus GG; Metronidazole; Recurrent Clostridium difficile associated disease; Saccharomyces boulardii; Vancomycin

Indexed keywords

ANION EXCHANGE RESIN; ANTIBIOTIC AGENT; BACTERIAL VACCINE; COLESTIPOL; COLESTYRAMINE; ENEMA; IMMUNOGLOBULIN; METRONIDAZOLE; PROBIOTIC AGENT; RIFAMPICIN; VANCOMYCIN;

ADJUVANT THERAPY; BACTERIAL STRAIN; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLON FLORA; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; HUMAN; INTESTINE LAVAGE; LACTOBACILLUS; MULTIPLE CYCLE TREATMENT; NASOGASTRIC TUBE; NEUROTOXICITY; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; SACCHAROMYCES BOULARDII; TREATMENT DURATION; TREATMENT PLANNING; VACCINATION;

EID: 33846016197     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Moskovitz M, Bartlett JG. Recurrent pseudomembranous colitis unassociated with prior antibiotic therapy. Ann Intern Med. 1981;141:663-664.
2. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-2441.
3. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442-2449.
4. Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis. 1997;24:324-333.
5. Barbut F, Richard A, Hamadi K, et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol. 2000;38:2386-2388.
6. Wilcox MH. Treatment of Clostridium difficile infection. J Antimicrob Chemother. 1998;41(suppl 3):41-46.
7. Gerding DN. Treatment of Clostridium difficile-associated diarrhea and colitis. Curr Top Microbiol Immunol. 2000;250:127-139.
8. McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999;20:43-50.
9. Do AN, Fridkin SK, Yechouron A, et al. Risk factors for early recurrent Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998;26:954-959.
10. O'Neill GL, Beaman MH, Riley TV. Relapse versus reinfection with Clostridium difficile. Epidemiol Infect. 1991;107:627-635.
11. Johnson S, Adelman A, Clabots CR, et al. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis. 1989;159:340-343.
12. Tang-Feldman Y, Mayo S, Silva J, et al. Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent Clostridium difficile-associated diarrhea. J Clin Microbiol. 2003;41:3413-3414.
13. Buggy BP, Fekety R, Silva J. Therapy of relapsing Clostridium difficile-associated diarrhea, and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol. 1987;9:155-159.
14. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769-1775.
15. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr. 2000;183:396S-402S.
16. Blehaut H, Massot J, Elmer GW, et al. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos. 1989;10:353-364.
17. Adam J et al. Essai's cliniques contrôlés en double insu de l'ultra-levure lyophilisée. Étude multicentrique par 25 medecins de 388 cas. Gaz Med Fr. 1977;84:2072-2081.
18. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology. 1989;96:981-988.
19. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of β-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol. 1995;90:439-448.
20. Elmer GW, McFarland LV. Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrob Agents Chemother. 1987;31:129-131.
21. Surawicz CM, McFarland LV, Elmer G, et al. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol. 1989;84:1285-1287.
22. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271:1913-1918.
23. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31:1012-1017.
24. Castagliuolo I, Riegler MF, Valenick L, et al. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. 1999;67:302-307.
25. Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology. 1993;104:1108-1115.
26. Qamar A, Aboudola S, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun. 2001;69:2762-2765.
27. Goldin BR, Gorbach SL, Saxelin M, et al. Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci. 1992;37:121-128.
28. Silva M, Jacobus NV, Deneke C, et al. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother. 1987;31:1231-1233.
29. Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet. 1987;2:1519.
30. Biller JA, Katz AJ, Flores AF, et al. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr. 1995;21:224-226.
31. Bennet RG, Laughon B, Lindsay J et al. Lactobacillus GG treatment of Clostridium difficile infection in nursing home patients. Abstract of the Third International Conference on Nosocomial Infection; Atlanta, Georgia; 1990.
32. Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol. 2000;95:S11-S13.
33. Wullt M, Hagslätt MJ, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis. 2003;35:365-367.
34. Bowden TA, Mansberger AR, Lykins LE. Pseudomembraneous enterocolitis: mechanism of restoring floral homeostasis. Am J Surg. 1981;47:178-183.
35. Schwan A, Sjölin S, Trottestam U, et al. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis. 1984;16:211-215.
36. Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol. 2000;95:3283-3285.
37. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36:580-585.
38. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989;1(8648):1156-1160.
39. Borriello SP, Barclay FE. Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains. J Med Microbiol. 1985;19:339-350.
40. Seal D, Borriello SP, Barclay F, et al. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol. 1987;6:51-53.
41. Martirosian G, Szczesny A, Cohen SH, Silva J Jr. Analysis of Clostridium difficile-associated diarrhea among patients hospitalized in tertiary care academic hospital. Diagnostic Microbiol Infect Dis. 2004;52:153-155.
42. Kreutzer EW, Milligan FD. Treatment of antibiotic-associated pseudomembranous colitis with cholestyramine resin. Johns Hopkins Med J. 1978;143:67-72.
43. Tedesco FJ, Napier J, Gamble W, et al. Therapy of antibiotic associated pseudomembranous colitis. J Clin Gastroenterol. 1979;1:51.
44. Keighley MRB. Antibiotic associated pseudomembranous colitis: pathogenesis and management. Drugs. 1980;20:49-56.
45. Tedesco FJ. Treatment of recurrent antibiotic-associated pseudomembranous colitis. Am J Gastroenterol. 1982;77:220-221.
46. Heerze LD, Kelm MA, Talbot JA, et al. Oligosaccharide sequences attached to an inert support (SYNSORB) as potential therapy for antibiotic-associated diarrhea and pseudomembranous colitis. J Infect Dis. 1994;169:291-296.
47. Braunlin W, Xu Q, Hook P, et al. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J. 2004;87:534-539.
48. Giannasca PJ, Warny M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine. 2004;22:848-856.
49. Warny M, Vaerman JP, Avesani V, et al. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun. 1994;62:384-389.
50. Aronsson B, Granström M, Möllby R, et al. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection. 1985;13:97-101.
51. Leung DYM, Kelly CP, Boguniewicz M, et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991;118:633-637.
52. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390-397.
53. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189-193.
54. Aboudola S, Kotloff KL, Kyne L, et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun. 2003;71:1608-1610.
55. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology. 2005;128:764-770.
56. Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut. 1997;41:366-370.
57. Beales ILP. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut. 2002;51:456.
58. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother. 2004;53:882-884.
59. Kelly CP, Pothoulakis C, Vavva F, et al. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother. 1996;40:373-379.
60. Lyerly DM, Bostwick EF, Binion SB, et al. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun. 1991;59:2215-2218.
61. King JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun. 1998;66:2018-2025.
62. Van Dissel JT, De Groot N, Hensgens CM, et al. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhea: preclinical and preliminary clinical data. J Med Microbiol. 2005;54(pt 2):197-205.
63. Liacouras CA, Piccoli DA. Whole-bowel irrigation as an adjunct to the treatment of chronic, relapsing Clostridium difficile colitis. J Clin Gostroenterol. 1996;22:186-189.